Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 100 |
|
|||||
| News | - | ||||||
| Day High | 2.20 | Low High |
|||||
| Day Low | 2.20 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Innate Pharma (PK) | IPHYF | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.20 | 16:00:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.20 | 2.20 | 2.20 | 2.20 | 2.20 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1 | 100 | $ 2.20 | $ 220 | - | 2.13 - 3.37 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:30:00 | 100 | $ 2.20 | USD |
Innate Pharma (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 185.17M | 38.14M | - | 61.64M | -7.57M | -0.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Innate Pharma (PK) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPHYF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.13 | 2.20 | 2.13 | 2.19 | 6,000 | 0.07 | 3.29% |
| 1 Month | 2.13 | 2.20 | 2.13 | 2.19 | 6,000 | 0.07 | 3.29% |
| 3 Months | 2.52 | 2.65 | 2.13 | 2.23 | 1,713 | -0.32 | -12.70% |
| 6 Months | 2.39 | 2.895 | 2.13 | 2.32 | 1,089 | -0.19 | -7.95% |
| 1 Year | 2.97 | 3.37 | 2.13 | 2.46 | 771 | -0.77 | -25.93% |
| 3 Years | 3.80 | 11.00 | 1.93 | 4.70 | 1,663 | -1.60 | -42.11% |
| 5 Years | 6.39 | 11.00 | 1.93 | 5.16 | 1,596 | -4.19 | -65.57% |
Innate Pharma (PK) Description
| Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris. |
